SEDI Insider filing browser
Filter by Company
×
Filter by $CAD Amount
×
Filter by Filing Type
Filter by Insider
×
 
Date Issuer Insider Transaction Amount New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
Filed 2022-05-25 17:22
Tx date 2022-05-25 		$ASP
Acerus Pharmaceuticals Corporation 		Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$31,350
+100 vol
$313.50 each 		2,500
Filed 2022-05-20 16:19
Tx date 2022-05-20 		$ASP
Acerus Pharmaceuticals Corporation 		Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$686.00
+200 vol
$3.43 each 		2,400
Filed 2022-05-19 14:49
Tx date 2022-05-19 		$ASP
Acerus Pharmaceuticals Corporation 		Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$363.50
+100 vol
$3.63 each 		2,200
Filed 2022-05-19 14:48
Tx date 2022-05-18 		$ASP
Acerus Pharmaceuticals Corporation 		Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$388.00
+100 vol
$3.88 each 		2,100
Filed 2022-05-19 14:45
Tx date 2022-05-12 		$ASP
Acerus Pharmaceuticals Corporation 		Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$7,594
+2,000 vol
$3.80 each 		2,000
Filed 2022-05-12 11:51
Tx date 2022-05-12 		$ASP
Acerus Pharmaceuticals Corporation 		Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$7,594
+2,000 vol
$3.80 each
Filed 2022-05-12 11:51
Tx date 2022-05-12 		$ASP
Acerus Pharmaceuticals Corporation 		Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$7,594
+2,000 vol
$3.80 each 		2,000
Filed 2022-05-12 11:51
Tx date 2022-03-07 		$ASP
Acerus Pharmaceuticals Corporation 		Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2022-05-11 14:56
Tx date 2022-05-11 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$2,260
+500 vol
$4.52 each 		79,482
Filed 2022-05-11 14:53
Tx date 2022-05-11 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$466.00
+100 vol
$4.66 each 		2,506
Filed 2022-05-11 14:53
Tx date 2022-05-11 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$453.00
+100 vol
$4.53 each 		2,406
Filed 2022-05-11 14:52
Tx date 2022-05-11 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$900.00
+200 vol
$4.50 each 		2,306
Filed 2022-05-11 14:52
Tx date 2022-05-11 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$440.00
+100 vol
$4.40 each 		2,106
Filed 2022-05-06 16:03
Tx date 2022-05-06 		$ASP
Acerus Pharmaceuticals Corporation 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
37 - Stock split or consolidation
-2,158,445 vol 		10,846
Filed 2022-05-06 16:02
Tx date 2022-05-06 		$ASP
Acerus Pharmaceuticals Corporation 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation
-485,013 vol 		2,437
Filed 2022-03-17 15:29
Tx date 2022-03-16 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
+3,961,218 vol 		15,796,540
Filed 2022-03-17 15:28
Tx date 2022-03-16 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
-3,961,218 vol 		0
Filed 2022-03-11 19:14
Tx date 2022-03-11 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Holder: 7th Merchant Corp (Indirect Ownership)
Common Shares
97 - Other
+927,092 vol 		927,092
Filed 2022-03-11 19:12
Tx date 2020-06-23 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Holder: 7th Merchant Corp (Indirect Ownership)
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2022-03-11 19:11
Tx date 2022-03-11 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Holder: 1680897 Ontario (Indirect Ownership)
Common Shares
97 - Other
-927,092 vol 		0
Filed 2022-03-11 19:07
Tx date 2022-03-11 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Holder: Gale Bale (Control or Direction)
Common Shares
97 - Other
-92,000 vol 		0
Filed 2021-07-06 19:44
Tx date 2021-06-29 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$150,963
+3,151,639 vol
$0.0479 each 		9,628,533
Filed 2021-07-06 19:41
Tx date 2021-06-29 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$1,035,178
+21,611,238 vol
$0.0479 each 		41,132,615
Filed 2021-07-06 19:37
Tx date 2021-06-29 		$ASP
Acerus Pharmaceuticals Corporation 		Sorli, Christopher Hutchins
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$136,316
+2,845,855 vol
$0.0479 each 		7,969,472
Filed 2021-07-06 19:33
Tx date 2021-06-29 		$ASP
Acerus Pharmaceuticals Corporation 		Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$95,053
+1,984,407 vol
$0.0479 each 		4,446,723
Filed 2021-07-06 19:30
Tx date 2021-06-29 		$ASP
Acerus Pharmaceuticals Corporation 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$185,469
+3,872,013 vol
$0.0479 each 		9,494,722
Filed 2021-07-06 19:26
Tx date 2021-06-29 		$ASP
Acerus Pharmaceuticals Corporation 		Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$209,551
+4,374,775 vol
$0.0479 each 		10,013,137
Filed 2020-12-18 07:37
Tx date 2020-12-16 		$ASP
Acerus Pharmaceuticals Corporation 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+1,569,291 vol 		2,169,291
Filed 2020-12-18 07:34
Tx date 2020-12-16 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights
+3,961,218 vol 		3,961,218
Filed 2020-12-18 07:32
Tx date 2018-05-01 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2020-12-18 07:29
Tx date 2020-12-16 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+1,569,291 vol 		1,569,291
Filed 2020-12-18 07:28
Tx date 2020-06-23 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2020-12-18 07:25
Tx date 2020-12-16 		$ASP
Acerus Pharmaceuticals Corporation 		Cotton, Geoffrey David
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+1,569,291 vol 		1,569,291
Filed 2020-12-18 07:24
Tx date 2020-05-04 		$ASP
Acerus Pharmaceuticals Corporation 		Cotton, Geoffrey David
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2020-12-18 07:14
Tx date 2020-12-16 		$ASP
Acerus Pharmaceuticals Corporation 		Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+1,143,218 vol 		2,462,316
Filed 2020-12-18 07:08
Tx date 2020-12-16 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+1,569,291 vol 		4,484,463
Filed 2020-12-04 13:37
Tx date 2020-11-26 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Holder: 1680897 Ontario (Indirect Ownership)
Common Shares
99 - Correction of information 		$7,937
+317,514 vol
$0.025 each 		927,092
Filed 2020-12-04 13:33
Tx date 2020-11-26 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption 		$46,784
+1,871,380 vol
$0.025 each 		5,464,133
Filed 2020-11-27 13:34
Tx date 2020-11-26 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption 		$57,309
+2,292,371 vol
$0.025 each
Filed 2020-11-30 10:41
Tx date 2020-11-26 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption 		$3,435
+137,431 vol
$0.025 each 		401,278
Filed 2020-11-27 13:41
Tx date 2020-11-26 		$ASP
Acerus Pharmaceuticals Corporation 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
16 - Acquisition or disposition under a prospectus exemption 		$12,734,214
+509,368,574 vol
$0.025 each 		1,376,502,750
Filed 2020-11-27 13:38
Tx date 2020-11-26 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption 		$78,133
+3,125,327 vol
$0.025 each 		4,551,727
Filed 2020-11-27 13:34
Tx date 2020-11-26 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption 		$57,309
+2,292,371 vol
$0.025 each 		5,885,124
Filed 2020-11-27 13:31
Tx date 2020-11-26 		$ASP
Acerus Pharmaceuticals Corporation 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption 		$748.75
+29,950 vol
$0.025 each 		487,450
Filed 2020-11-27 13:18
Tx date 2020-11-26 		$ASP
Acerus Pharmaceuticals Corporation 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption 		$614.63
+24,585 vol
$0.025 each 		71,785
Filed 2020-11-27 13:06
Tx date 2020-11-26 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption 		$34,090
+1,363,616 vol
$0.025 each 		11,835,322
Filed 2020-11-16 10:24
Tx date 2020-11-13 		$ASP
Acerus Pharmaceuticals Corporation 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$12,000
+400,000 vol
$0.03 each 		457,500
Filed 2020-09-14 14:34
Tx date 2020-09-09 		$ASP
Acerus Pharmaceuticals Corporation 		Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$68,593
+1,319,098 vol
$0.052 each 		1,319,098
Filed 2020-09-14 14:31
Tx date 2020-09-08 		$ASP
Acerus Pharmaceuticals Corporation 		Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2020-08-17 16:49
Tx date 2020-08-12 		$ASP
Acerus Pharmaceuticals Corporation 		Sorli, Christopher Hutchins
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$303,830
+5,123,617 vol
$0.0593 each 		5,123,617
Filed 2020-08-17 16:47
Tx date 2020-08-03 		$ASP
Acerus Pharmaceuticals Corporation 		Sorli, Christopher Hutchins
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2020-06-28 18:41
Tx date 2020-06-23 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Holder: Gale Bale (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report 		92,000
Filed 2020-06-28 18:41
Tx date 2020-06-23 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Holder: Elizabeth Carlson (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report 		106,657
Filed 2020-06-28 18:40
Tx date 2020-06-23 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Holder: 1680897 Ontario (Indirect Ownership)
Common Shares
00 - Opening Balance-Initial SEDI Report 		609,578
Filed 2020-06-28 18:39
Tx date 2020-06-23 		$ASP
Acerus Pharmaceuticals Corporation 		Leckie, William Scott
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report 		3,592,753
Filed 2020-04-02 18:07
Tx date 2020-03-30 		$ASP
Acerus Pharmaceuticals Corporation 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$187,490
+4,148,017 vol
$0.0452 each 		5,622,709
Filed 2020-04-02 18:03
Tx date 2020-03-30 		$ASP
Acerus Pharmaceuticals Corporation 		Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$235,452
+5,209,137 vol
$0.0452 each 		5,638,362
Filed 2020-04-02 17:59
Tx date 2020-03-30 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$837,166
+18,521,377 vol
$0.0452 each 		19,521,377
Filed 2020-04-02 17:56
Tx date 2020-03-30 		$ASP
Acerus Pharmaceuticals Corporation 		Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options 		$104,645
+2,315,172 vol
$0.0452 each 		2,715,172
Filed 2020-04-02 17:42
Tx date 2020-03-30 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options 		$104,645
+2,315,172 vol
$0.0452 each 		2,915,172
Filed 2020-04-02 17:38
Tx date 2020-03-30 		$ASP
Acerus Pharmaceuticals Corporation 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options 		$104,645
+2,315,172 vol
$0.0452 each 		2,915,172
Filed 2020-04-02 17:33
Tx date 2020-03-30 		$ASP
Acerus Pharmaceuticals Corporation 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
50 - Grant of options 		$104,645
+2,315,172 vol
$0.0452 each 		2,940,172
Filed 2020-04-02 17:16
Tx date 2020-03-30 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$244,173
+5,402,068 vol
$0.0452 each 		6,476,894
Filed 2020-03-11 11:53
Tx date 2020-03-11 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options
-25,000 vol 		600,000
Filed 2020-02-21 17:04
Tx date 2020-02-21 		$ASP
Acerus Pharmaceuticals Corporation 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
11 - Acquisition or disposition carried out privately
+749,230,776 vol 		867,134,176
Filed 2019-12-13 14:18
Tx date 2019-03-10 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options
-25,000 vol 		625,000
Filed 2019-12-13 14:16
Tx date 2018-04-26 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options
-25,000 vol 		450,000
Filed 2019-12-13 14:15
Tx date 2017-03-12 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options
-25,000 vol 		375,000
Filed 2019-12-13 14:14
Tx date 2016-07-16 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options
-25,000 vol 		200,000
Filed 2019-12-12 10:24
Tx date 2019-03-10 		$ASP
Acerus Pharmaceuticals Corporation 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
52 - Expiration of options
-25,000 vol 		625,000
Filed 2019-12-12 10:22
Tx date 2018-11-06 		$ASP
Acerus Pharmaceuticals Corporation 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
52 - Expiration of options
-25,000 vol 		450,000
Filed 2019-11-04 10:38
Tx date 2019-11-01 		$ASP
Acerus Pharmaceuticals Corporation 		Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,600
+20,000 vol
$0.08 each 		61,000
Filed 2019-11-04 10:38
Tx date 2019-10-21 		$ASP
Acerus Pharmaceuticals Corporation 		Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$85.00
+1,000 vol
$0.085 each 		41,000
Filed 2019-10-17 15:53
Tx date 2019-10-17 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$12,350
+130,000 vol
$0.095 each 		10,471,706
Filed 2019-08-12 10:06
Tx date 2019-08-08 		$ASP
Acerus Pharmaceuticals Corporation 		Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+429,225 vol 		429,225
Filed 2019-08-12 10:04
Tx date 2019-05-31 		$ASP
Acerus Pharmaceuticals Corporation 		Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2019-08-09 16:01
Tx date 2019-08-08 		$ASP
Acerus Pharmaceuticals Corporation 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$4,860
+40,500 vol
$0.12 each 		129,000
Filed 2019-08-09 15:56
Tx date 2019-08-08 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+324,826 vol 		1,074,826
Filed 2019-08-09 15:49
Tx date 2019-08-08 		$ASP
Acerus Pharmaceuticals Corporation 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+249,420 vol 		1,474,692
Filed 2019-03-29
Tx date 2019-03-29 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately 		$1,000,000
+5,128,206 vol
$0.195 each 		10,341,706
Filed 2019-03-29
Tx date 2019-03-29 		$ASP
Acerus Pharmaceuticals Corporation 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
11 - Acquisition or disposition carried out privately 		$3,000,000
+15,384,616 vol
$0.195 each 		117,903,400
Filed 2019-03-29
Tx date 2019-03-29 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
11 - Acquisition or disposition carried out privately 		$500,000
+2,564,103 vol
$0.195 each 		4,558,730
Filed 2019-03-29
Tx date 2019-03-29 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately 		$30,000
+153,847 vol
$0.195 each 		263,847
Filed 2019-03-07
Tx date 2019-03-06 		$ASP
Acerus Pharmaceuticals Corporation 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options 		$26,000
+200,000 vol
$0.13 each 		600,000
Filed 2019-03-07
Tx date 2019-03-06 		$ASP
Acerus Pharmaceuticals Corporation 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
50 - Grant of options 		$26,000
+200,000 vol
$0.13 each 		675,000
Filed 2019-03-07
Tx date 2019-03-06 		$ASP
Acerus Pharmaceuticals Corporation 		Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options 		$26,000
+200,000 vol
$0.13 each 		400,000
Filed 2019-03-07
Tx date 2019-03-06 		$ASP
Acerus Pharmaceuticals Corporation 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options 		$26,000
+200,000 vol
$0.13 each 		600,000
Filed 2019-03-07
Tx date 2019-03-06 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options 		$26,000
+200,000 vol
$0.13 each 		725,000
Filed 2018-12-28
Tx date 2018-12-27 		$ASP
Acerus Pharmaceuticals Corporation 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$3,135
+28,500 vol
$0.11 each 		88,500
Filed 2018-12-26
Tx date 2018-12-24 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$49,463
+429,000 vol
$0.1153 each 		1,994,627
Filed 2018-12-20
Tx date 2018-12-20 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$11,990
+100,000 vol
$0.1199 each 		5,213,500
Filed 2018-12-17
Tx date 2018-12-17 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$29,315
+225,500 vol
$0.13 each 		5,113,500
Filed 2018-12-11
Tx date 2018-12-10 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$2,632
+19,500 vol
$0.135 each 		1,535,127
Filed 2018-12-11
Tx date 2018-12-11 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$4,117
+30,500 vol
$0.135 each 		1,565,627
Filed 2018-12-07
Tx date 2018-12-07 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$43,200
+320,000 vol
$0.135 each 		1,515,627
Filed 2018-12-07
Tx date 2018-12-07 		$ASP
Acerus Pharmaceuticals Corporation 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,917
+14,200 vol
$0.135 each 		47,200
Filed 2018-11-30
Tx date 2018-11-30 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$2,320
+14,500 vol
$0.16 each 		109,500
Filed 2018-11-30
Tx date 2018-11-30 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$77.50
+500 vol
$0.155 each 		110,000
Filed 2018-11-21
Tx date 2018-11-21 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,800
+10,000 vol
$0.18 each 		95,000
Filed 2018-11-20
Tx date 2018-11-20 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,600
+10,000 vol
$0.16 each 		85,000
Filed 2018-11-19
Tx date 2018-11-19 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$12,750
+75,000 vol
$0.17 each 		75,000
Filed 2018-11-19
Tx date 2018-10-30 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2018-11-19
Tx date 2018-10-30 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-11-19
Tx date 2018-11-19 		$ASP
Acerus Pharmaceuticals Corporation 		Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+750,000 vol 		750,000
Filed 2018-09-11
Tx date 2018-09-07 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$5,760
+24,000 vol
$0.24 each 		1,101,627
Filed 2018-09-11
Tx date 2018-09-10 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$22,560
+94,000 vol
$0.24 each 		1,195,627
Filed 2018-09-07
Tx date 2018-09-07 		$ASP
Acerus Pharmaceuticals Corporation 		Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$3,640
+14,000 vol
$0.26 each 		40,000
Filed 2018-08-31
Tx date 2018-08-29 		$ASP
Acerus Pharmaceuticals Corporation 		Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$560.00
+2,000 vol
$0.28 each 		6,000
Filed 2018-08-31
Tx date 2018-08-30 		$ASP
Acerus Pharmaceuticals Corporation 		Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$5,600
+20,000 vol
$0.28 each 		26,000
Filed 2018-08-29
Tx date 2018-08-28 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$115,199
+400,000 vol
$0.288 each 		4,888,000
Filed 2018-08-29
Tx date 2017-12-06 		$ASP
Acerus Pharmaceuticals Corporation 		Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-08-29
Tx date 2018-08-28 		$ASP
Acerus Pharmaceuticals Corporation 		Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,120
+4,000 vol
$0.28 each 		4,000
Filed 2018-08-28
Tx date 2018-08-24 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$49,035
+175,000 vol
$0.2802 each 		4,264,000
Filed 2018-08-28
Tx date 2018-08-28 		$ASP
Acerus Pharmaceuticals Corporation 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$5,600
+20,000 vol
$0.28 each 		60,000
Filed 2018-08-28
Tx date 2018-08-27 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$62,720
+224,000 vol
$0.28 each 		4,488,000
Filed 2018-08-24
Tx date 2018-08-23 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$80,621
+281,500 vol
$0.2864 each 		4,089,000
Filed 2018-08-24
Tx date 2018-08-21 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$125,222
+445,000 vol
$0.2814 each 		2,561,000
Filed 2018-08-24
Tx date 2018-08-22 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$142,545
+496,500 vol
$0.2871 each 		3,807,500
Filed 2018-08-24
Tx date 2018-08-21 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$217,499
+750,000 vol
$0.29 each 		3,311,000
Filed 2018-08-24
Tx date 2018-08-20 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$50,187
+186,500 vol
$0.2691 each 		2,116,000
Filed 2018-08-22
Tx date 2018-08-21 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$10,080
+42,000 vol
$0.24 each 		1,077,627
Filed 2018-08-20
Tx date 2018-08-15 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+1,000,000 vol 		1,000,000
Filed 2018-08-20
Tx date 2018-08-17 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$215,690
+769,500 vol
$0.2803 each 		1,929,500
Filed 2018-08-20
Tx date 2018-08-15 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$38,720
+176,000 vol
$0.22 each 		176,000
Filed 2018-08-20
Tx date 2018-05-01 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-08-20
Tx date 2018-08-17 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$9,450
+35,000 vol
$0.27 each 		1,035,627
Filed 2018-08-20
Tx date 2018-05-01 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2018-08-20
Tx date 2018-08-16 		$ASP
Acerus Pharmaceuticals Corporation 		Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$230,157
+984,000 vol
$0.2339 each 		1,160,000
Filed 2018-08-15
Tx date 2018-08-15 		$ASP
Acerus Pharmaceuticals Corporation 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$15,840
+72,000 vol
$0.22 each 		559,900
Filed 2018-08-15
Tx date 2018-08-15 		$ASP
Acerus Pharmaceuticals Corporation 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$5,880
+28,000 vol
$0.21 each 		487,900
Filed 2018-05-17
Tx date 2015-12-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2018-05-17
Tx date 2015-12-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2018-05-17
Tx date 2015-12-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report 		57,500
Filed 2018-05-17
Tx date 2015-12-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market 		$81.00
+300 vol
$0.27 each 		26,800
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+316,598 vol 		1,316,598
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$20,412
+72,900 vol
$0.28 each 		459,900
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market 		$7,287
+26,500 vol
$0.275 each 		26,500
Filed 2018-03-26
Tx date 2017-06-01 		$ASP
Acerus Pharmaceuticals Corporation 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+334,863 vol 		1,634,863
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+225,272 vol 		1,225,272
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		1,175,000
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+75,000 vol 		1,075,000
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		475,000
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		525,000
Filed 2018-03-26
Tx date 2018-03-22 		$ASP
Acerus Pharmaceuticals Corporation 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$99,184
+374,000 vol
$0.2652 each 		1,000,627
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		400,000
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+316,598 vol 		2,701,598
Filed 2018-03-26
Tx date 2018-03-23 		$ASP
Acerus Pharmaceuticals Corporation 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		400,000
Filed 2018-03-21
Tx date 2017-03-10 		$ASP
Acerus Pharmaceuticals Corporation 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+200,000 vol 		300,000
Filed 2017-12-27
Tx date 2017-12-27 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$14,324
+50,000 vol
$0.2865 each 		3,002,100
Filed 2017-12-27
Tx date 2017-12-27 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$8,339
+27,900 vol
$0.2989 each 		3,030,000
Filed 2017-12-21
Tx date 2017-12-18 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RESP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market 		$14,910
+49,700 vol
$0.30 each 		49,700
Filed 2017-12-21
Tx date 2017-06-01 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RESP (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-12-11
Tx date 2017-12-06 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-12-11
Tx date 2017-12-06 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options 		$72,000
+200,000 vol
$0.36 each 		200,000
Filed 2017-12-01
Tx date 2017-11-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$29,202
+157,000 vol
$0.186 each 		1,213,500
Filed 2017-12-01
Tx date 2017-11-27 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$40,929
+194,900 vol
$0.21 each 		1,426,400
Filed 2017-12-01
Tx date 2017-11-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$3,200
+16,000 vol
$0.20 each 		1,231,500
Filed 2017-12-01
Tx date 2017-11-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$390.00
+2,000 vol
$0.195 each 		1,215,500
Filed 2017-12-01
Tx date 2017-11-23 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$20,760
+120,000 vol
$0.173 each 		1,056,500
Filed 2017-12-01
Tx date 2017-11-23 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$4,845
+28,500 vol
$0.17 each 		936,500
Filed 2017-11-21
Tx date 2017-11-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$5,440
+32,000 vol
$0.17 each 		191,000
Filed 2017-11-21
Tx date 2017-11-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$33,320
+196,000 vol
$0.17 each 		387,000
Filed 2017-11-20
Tx date 2017-11-17 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$918.00
+5,100 vol
$0.18 each 		2,952,100
Filed 2017-11-20
Tx date 2017-11-15 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$300.00
+2,000 vol
$0.15 each 		2,947,000
Filed 2017-11-17
Tx date 2017-11-14 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,812
+12,500 vol
$0.145 each 		149,500
Filed 2017-11-17
Tx date 2017-11-15 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,330
+9,500 vol
$0.14 each 		159,000
Filed 2017-11-17
Tx date 2017-11-13 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$8,680
+62,000 vol
$0.14 each 		137,000
Filed 2017-11-15
Tx date 2016-07-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-11-15
Tx date 2017-11-15 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$4,950
+33,000 vol
$0.15 each 		33,000
Filed 2017-11-13
Tx date 2017-11-09 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$62,500
+500,000 vol
$0.125 each 		2,695,000
Filed 2017-11-13
Tx date 2017-06-01 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-11-13
Tx date 2017-11-09 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$60,000
+500,000 vol
$0.12 each 		1,300,000
Filed 2017-11-13
Tx date 2017-11-09 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$60,000
+500,000 vol
$0.12 each 		1,000,000
Filed 2017-11-13
Tx date 2017-11-09 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$9,750
+75,000 vol
$0.13 each 		75,000
Filed 2017-11-13
Tx date 2017-11-09 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$60,000
+500,000 vol
$0.12 each 		1,000,000
Filed 2017-11-13
Tx date 2017-11-09 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$24,000
+200,000 vol
$0.12 each 		1,000,000
Filed 2017-11-13
Tx date 2017-11-09 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$60,000
+500,000 vol
$0.12 each 		800,000
Filed 2017-11-13
Tx date 2017-11-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$13,095
+97,000 vol
$0.135 each 		2,945,000
Filed 2017-11-13
Tx date 2017-11-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$18,135
+139,500 vol
$0.13 each 		2,848,000
Filed 2017-11-13
Tx date 2017-11-09 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,620
+13,500 vol
$0.12 each 		2,708,500
Filed 2017-11-13
Tx date 2017-11-09 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$60,000
+500,000 vol
$0.12 each 		2,385,000
Filed 2017-09-01
Tx date 2017-08-28 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$30,245
+263,000 vol
$0.115 each 		908,000
Filed 2017-06-06
Tx date 2017-06-01 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+500,000 vol 		500,000
Filed 2017-06-06
Tx date 2017-06-01 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-06-02
Tx date 2017-06-02 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$4,680
+39,000 vol
$0.12 each 		424,500
Filed 2017-05-24
Tx date 2017-05-17 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+900,000 vol 		8,048,325
Filed 2017-03-24
Tx date 2017-03-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$1,782
+15,500 vol
$0.115 each 		512,127
Filed 2017-03-24
Tx date 2017-03-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$2,127
+18,500 vol
$0.115 each 		626,627
Filed 2017-03-24
Tx date 2017-03-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$11,040
+96,000 vol
$0.115 each 		608,127
Filed 2017-03-14
Tx date 2017-03-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+200,000 vol 		300,000
Filed 2017-03-13
Tx date 2017-03-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+200,000 vol 		500,000
Filed 2017-03-13
Tx date 2017-03-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+300,000 vol 		800,000
Filed 2017-03-13
Tx date 2017-03-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$11,000
+100,000 vol
$0.11 each 		385,500
Filed 2017-03-13
Tx date 2017-03-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+600,000 vol 		1,885,000
Filed 2017-03-13
Tx date 2017-03-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+200,000 vol 		425,000
Filed 2017-03-13
Tx date 2017-03-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
50 - Grant of options
+200,000 vol 		375,000
Filed 2017-03-13
Tx date 2017-03-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+200,000 vol 		300,000
Filed 2017-03-13
Tx date 2017-03-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+2,000,000 vol 		7,148,325
Filed 2016-12-08
Tx date 2016-12-06 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$11,875
+95,000 vol
$0.125 each 		2,195,000
Filed 2016-11-23
Tx date 2016-11-23 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$14,729
+100,000 vol
$0.1473 each 		285,500
Filed 2016-11-14
Tx date 2016-11-14 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$13,000
+100,000 vol
$0.13 each 		2,100,000
Filed 2016-11-08
Tx date 2016-11-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options 		$90,000
+500,000 vol
$0.18 each 		500,000
Filed 2016-11-08
Tx date 2016-11-01 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-11-04
Tx date 2016-11-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$2,550
+15,000 vol
$0.17 each 		40,000
Filed 2016-08-23
Tx date 2016-08-23 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+325,000 vol 		5,148,325
Filed 2016-08-23
Tx date 2016-08-23 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$9,600
+60,000 vol
$0.16 each 		185,500
Filed 2016-08-22
Tx date 2016-08-19 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$49,000
+350,000 vol
$0.14 each 		645,000
Filed 2016-08-17
Tx date 2016-08-16 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$90,000
+1,000,000 vol
$0.09 each 		2,000,000
Filed 2016-08-12
Tx date 2016-08-11 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+300,000 vol 		300,000
Filed 2016-08-12
Tx date 2016-07-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-08-12
Tx date 2016-08-11 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		100,000
Filed 2016-08-12
Tx date 2016-07-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-08-12
Tx date 2016-08-11 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$2,250
+25,000 vol
$0.09 each 		25,000
Filed 2016-08-12
Tx date 2015-06-26 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2016-07-27
Tx date 2016-07-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Mainville, Luc
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report 		1,000,000
Filed 2016-06-22
Tx date 2016-06-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$2,080
+16,000 vol
$0.13 each 		291,000
Filed 2016-06-22
Tx date 2016-06-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$12,900
+100,000 vol
$0.129 each 		275,000
Filed 2016-06-22
Tx date 2016-06-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$7,800
+60,000 vol
$0.13 each 		125,500
Filed 2016-06-10
Tx date 2016-06-09 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-175,603.80
-1,463,365 vol
$0.12 each 		20,913,418
Filed 2016-06-10
Tx date 2016-06-08 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-40,560
-312,000 vol
$0.13 each 		22,376,783
Filed 2016-06-10
Tx date 2016-06-08 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-11,000
-88,000 vol
$0.125 each 		22,688,783
Filed 2016-06-10
Tx date 2016-06-07 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-202.50
-1,500 vol
$0.135 each 		22,776,783
Filed 2016-06-10
Tx date 2016-06-07 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-47,645
-366,500 vol
$0.13 each 		22,778,283
Filed 2016-06-10
Tx date 2016-06-03 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-1,417.50
-10,500 vol
$0.135 each 		23,144,783
Filed 2016-06-10
Tx date 2016-06-03 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-2,622
-20,000 vol
$0.1311 each 		23,155,283
Filed 2016-06-10
Tx date 2016-06-03 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-26,260
-202,000 vol
$0.13 each 		23,175,283
Filed 2016-06-10
Tx date 2016-06-01 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-13,702.50
-101,500 vol
$0.135 each 		23,377,283
Filed 2016-06-10
Tx date 2016-06-01 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-25,225.10
-193,000 vol
$0.1307 each 		23,478,783
Filed 2016-06-10
Tx date 2016-06-01 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-26,715
-205,500 vol
$0.13 each 		23,671,783
Filed 2016-06-10
Tx date 2016-05-31 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-652.50
-4,500 vol
$0.145 each 		23,877,283
Filed 2016-06-10
Tx date 2016-05-31 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-22,680
-162,000 vol
$0.14 each 		23,881,783
Filed 2016-06-10
Tx date 2016-05-25 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-2,100
-14,000 vol
$0.15 each 		24,043,783
Filed 2016-06-10
Tx date 2016-05-25 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-1,160
-8,000 vol
$0.145 each 		24,057,783
Filed 2016-06-10
Tx date 2016-05-25 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-25,311
-177,000 vol
$0.143 each 		24,065,783
Filed 2016-06-10
Tx date 2016-05-25 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-16,100
-115,000 vol
$0.14 each 		24,242,783
Filed 2016-06-10
Tx date 2016-05-25 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-3,808
-28,000 vol
$0.136 each 		24,357,783
Filed 2016-06-10
Tx date 2016-05-25 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-6,345
-47,000 vol
$0.135 each 		24,385,783
Filed 2016-06-10
Tx date 2016-05-25 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-14,430
-111,000 vol
$0.13 each 		24,432,783
Filed 2016-06-10
Tx date 2016-05-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-1,520
-9,500 vol
$0.16 each 		24,543,783
Filed 2016-06-10
Tx date 2016-05-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-2,340
-15,000 vol
$0.156 each 		24,553,283
Filed 2016-06-10
Tx date 2016-05-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-17,592.50
-113,500 vol
$0.155 each 		24,568,283
Filed 2016-06-10
Tx date 2016-05-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-17,475
-116,500 vol
$0.15 each 		24,681,783
Filed 2016-06-10
Tx date 2016-05-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-8,047.50
-55,500 vol
$0.145 each 		24,798,283
Filed 2016-06-10
Tx date 2016-05-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-5,760
-40,000 vol
$0.144 each 		24,853,783
Filed 2016-06-10
Tx date 2016-05-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-10,850
-77,500 vol
$0.14 each 		24,893,783
Filed 2016-06-10
Tx date 2016-05-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-810.00
-6,000 vol
$0.135 each 		24,971,283
Filed 2016-06-10
Tx date 2016-05-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-2,620
-20,000 vol
$0.131 each 		24,977,283
Filed 2016-06-10
Tx date 2016-05-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-1,690
-13,000 vol
$0.13 each 		24,997,283
Filed 2016-06-10
Tx date 2016-05-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-16,275
-105,000 vol
$0.155 each 		25,010,283
Filed 2016-06-10
Tx date 2016-05-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-43,650
-291,000 vol
$0.15 each 		25,115,283
Filed 2016-06-10
Tx date 2016-05-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-59,914.80
-396,000 vol
$0.1513 each
Filed 2016-06-10
Tx date 2016-05-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-59,914.80
-396,000 vol
$0.1513 each
Filed 2016-06-10
Tx date 2016-05-19 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-23,471.50
-149,500 vol
$0.157 each 		25,406,283
Filed 2016-06-10
Tx date 2016-05-19 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-1,650
-10,000 vol
$0.165 each 		25,555,783
Filed 2016-06-10
Tx date 2016-05-19 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-12,880
-80,500 vol
$0.16 each 		25,565,783
Filed 2016-06-10
Tx date 2016-05-19 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-11,547.50
-74,500 vol
$0.155 each 		25,646,283
Filed 2016-06-10
Tx date 2016-05-19 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-27,825
-185,500 vol
$0.15 each 		25,720,783
Filed 2016-06-10
Tx date 2016-05-16 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-8,840
-52,000 vol
$0.17 each 		25,906,283
Filed 2016-06-10
Tx date 2016-05-16 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-47,025
-285,000 vol
$0.165 each 		25,958,283
Filed 2016-06-10
Tx date 2016-05-16 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-18,080
-113,000 vol
$0.16 each 		26,243,283
Filed 2016-06-10
Tx date 2016-05-16 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-7,750
-50,000 vol
$0.155 each 		26,356,283
Filed 2016-06-10
Tx date 2016-05-11 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-10,725
-65,000 vol
$0.165 each 		26,406,283
Filed 2016-06-10
Tx date 2016-05-11 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-1,920
-12,000 vol
$0.16 each 		26,471,283
Filed 2016-06-10
Tx date 2016-05-11 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-2,635
-17,000 vol
$0.155 each 		26,483,283
Filed 2016-06-10
Tx date 2016-05-11 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-16,425
-109,500 vol
$0.15 each 		26,500,283
Filed 2016-06-10
Tx date 2016-05-11 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-22,620
-156,000 vol
$0.145 each 		26,609,783
Filed 2016-06-10
Tx date 2016-05-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-2,635
-15,500 vol
$0.17 each 		26,765,783
Filed 2016-06-10
Tx date 2016-05-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-3,630
-22,000 vol
$0.165 each 		26,781,283
Filed 2016-06-10
Tx date 2016-05-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-20,480
-128,000 vol
$0.16 each 		26,803,283
Filed 2016-06-10
Tx date 2016-05-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-12,400
-80,000 vol
$0.155 each 		26,931,283
Filed 2016-06-10
Tx date 2016-05-10 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-47,550
-317,000 vol
$0.15 each 		27,011,283
Filed 2016-06-10
Tx date 2016-03-31 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-701.25
-8,500 vol
$0.0825 each
Filed 2016-06-10
Tx date 2016-03-31 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-701.25
-8,500 vol
$0.0825 each
Filed 2016-06-10
Tx date 2016-03-31 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-54,280
-678,500 vol
$0.08 each
Filed 2016-06-10
Tx date 2016-03-31 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-54,280
-678,500 vol
$0.08 each
Filed 2016-06-10
Tx date 2016-03-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-1,330
-14,000 vol
$0.095 each 		27,328,283
Filed 2016-06-10
Tx date 2016-03-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-16,830
-187,000 vol
$0.09 each 		27,342,283
Filed 2016-06-10
Tx date 2016-03-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-1,925
-22,000 vol
$0.0875 each 		27,529,283
Filed 2016-06-10
Tx date 2016-03-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-7,650
-90,000 vol
$0.085 each 		27,551,283
Filed 2016-06-10
Tx date 2016-03-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-701.25
-8,500 vol
$0.0825 each 		27,641,283
Filed 2016-06-10
Tx date 2016-03-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-54,280
-678,500 vol
$0.08 each 		27,649,783
Filed 2016-06-10
Tx date 2016-03-17 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-8,455
-89,000 vol
$0.095 each 		28,328,283
Filed 2016-06-10
Tx date 2016-03-17 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-24,795
-275,500 vol
$0.09 each 		28,417,283
Filed 2016-06-10
Tx date 2016-03-17 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-19,975
-235,000 vol
$0.085 each 		28,692,783
Filed 2016-06-10
Tx date 2016-03-17 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-32,040
-400,500 vol
$0.08 each 		28,927,783
Filed 2016-05-18
Tx date 2016-05-13 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
11 - Acquisition or disposition carried out privately 		$10,246,388
+51,437,691 vol
$0.1992 each 		102,518,784
Filed 2016-05-17
Tx date 2016-05-13 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
-36,979,391 vol 		0
Filed 2016-03-31
Tx date 2016-03-28 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$7,400
+74,000 vol
$0.10 each 		51,081,093
Filed 2016-03-31
Tx date 2016-03-28 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$368,000
+2,944,000 vol
$0.125 each 		51,007,093
Filed 2016-03-31
Tx date 2016-03-28 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$31,780
+227,000 vol
$0.14 each 		496,627
Filed 2016-03-31
Tx date 2016-03-28 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$1,690
+13,000 vol
$0.13 each 		269,627
Filed 2016-03-31
Tx date 2016-03-28 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$1,200
+10,000 vol
$0.12 each 		256,627
Filed 2016-03-30
Tx date 2016-03-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$4,500
+45,000 vol
$0.10 each 		65,500
Filed 2016-03-28
Tx date 2016-03-24 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$25,840
+272,000 vol
$0.095 each 		48,063,093
Filed 2016-03-28
Tx date 2016-03-23 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market 		$17,010
+189,000 vol
$0.09 each 		47,791,093
Filed 2016-03-09
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Vejvoda, Josef
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options 		$10,000
+100,000 vol
$0.10 each 		100,000
Filed 2016-03-09
Tx date 2015-12-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Vejvoda, Josef
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-03-08
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Sherman, Jeffrey Dennis
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		225,000
Filed 2016-03-08
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+2,000,000 vol 		4,823,325
Filed 2016-03-08
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Reininghaus, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		1,392,500
Filed 2016-03-08
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Quintyne, Arlene
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		154,865
Filed 2016-03-08
Tx date 2015-12-31 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Quintyne, Arlene
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report 		54,865
Filed 2016-03-08
Tx date 2015-12-31 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Quintyne, Arlene
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report 		12,500
Filed 2016-03-08
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		175,000
Filed 2016-03-08
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Hawkins, Matthew
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+950,000 vol 		1,585,000
Filed 2016-03-08
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		225,000
Filed 2016-03-08
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		100,000
Filed 2016-03-08
Tx date 2015-12-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-03-08
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bumby, Michael Scott
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+400,000 vol 		600,000
Filed 2016-03-08
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options
+950,000 vol 		1,285,000
Filed 2016-03-08
Tx date 2016-03-04 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
+100,000 vol 		100,000
Filed 2016-03-08
Tx date 2015-06-26 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-01-08
Tx date 2016-01-06 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-2,080
-13,000 vol
$0.16 each 		29,328,283
Filed 2016-01-08
Tx date 2016-01-06 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-6,510
-42,000 vol
$0.155 each 		29,341,283
Filed 2016-01-08
Tx date 2016-01-06 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-29,250
-195,000 vol
$0.15 each 		29,383,283
Filed 2016-01-08
Tx date 2016-01-05 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-5,130
-28,500 vol
$0.18 each 		29,578,283
Filed 2016-01-08
Tx date 2016-01-05 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-262.50
-1,500 vol
$0.175 each 		29,606,783
Filed 2016-01-08
Tx date 2016-01-05 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-4,590
-27,000 vol
$0.17 each 		29,608,283
Filed 2016-01-08
Tx date 2016-01-05 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-11,440
-71,500 vol
$0.16 each 		29,635,283
Filed 2016-01-08
Tx date 2016-01-05 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-1,705
-11,000 vol
$0.155 each 		29,706,783
Filed 2016-01-08
Tx date 2016-01-05 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$-16,575
-110,500 vol
$0.15 each 		29,717,783
Filed 2016-01-04
Tx date 2015-12-31 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market 		$-62,400
-520,000 vol
$0.12 each 		36,979,391
Filed 2016-01-03
Tx date 2015-12-30 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market 		$-40,152
-280,000 vol
$0.1434 each 		37,499,391
Filed 2015-12-30
Tx date 2015-12-29 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market 		$-28,940
-200,000 vol
$0.1447 each 		37,779,391
Filed 2015-12-29
Tx date 2015-12-29 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$4,200
+28,000 vol
$0.15 each 		295,000
Filed 2015-12-29
Tx date 2015-12-29 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,739
+12,000 vol
$0.145 each 		267,000
Filed 2015-12-29
Tx date 2015-12-22 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$11,900
+85,000 vol
$0.14 each 		255,000
Filed 2015-12-29
Tx date 2015-12-22 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$16,675
+115,000 vol
$0.145 each 		170,000
Filed 2015-12-25
Tx date 2015-12-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Vejvoda, Josef
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report 		230,000
Filed 2015-12-23
Tx date 2015-12-20 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Chabursky, Borys
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report 		57,500
Filed 2015-12-23
Tx date 2015-12-23 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,575
+9,000 vol
$0.175 each 		20,500
Filed 2015-12-23
Tx date 2015-12-23 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,190
+7,000 vol
$0.17 each 		11,500
Filed 2015-12-21
Tx date 2015-12-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report 		37,979,391
Filed 2015-09-24
Tx date 2015-09-22 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Pfeffer, Matthew Jonathan
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$8,000
+20,000 vol
$0.40 each 		20,000
Filed 2015-09-24
Tx date 2013-11-27 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Pfeffer, Matthew Jonathan
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2015-09-24
Tx date 2015-09-23 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$8,000
+20,000 vol
$0.40 each 		55,000
Filed 2015-09-24
Tx date 2015-09-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$2,905
+7,000 vol
$0.415 each 		35,000
Filed 2015-09-24
Tx date 2015-09-21 		$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) 		Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market 		$1,260
+3,000 vol
$0.42 each 		28,000